| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study
|
Thomas, Robert
|
|
2018
|
171 |
1 |
p. 103-110
|
artikel
|
| 2 |
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial
|
Santa-Maria, Cesar A.
|
|
2018
|
171 |
1 |
p. 121-129
|
artikel
|
| 3 |
Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors
|
Huang, Zhezhou
|
|
2018
|
171 |
1 |
p. 189-198
|
artikel
|
| 4 |
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
|
Wunderle, Marius
|
|
2018
|
171 |
1 |
p. 85-94
|
artikel
|
| 5 |
Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database
|
Elmi, Maryam
|
|
2018
|
171 |
1 |
p. 217-223
|
artikel
|
| 6 |
Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients
|
Tsunashima, Ryo
|
|
2018
|
171 |
1 |
p. 33-41
|
artikel
|
| 7 |
Effect of glucocorticoid use on survival in patients with stage I–III breast cancer
|
Lin, Ching-Hung
|
|
2018
|
171 |
1 |
p. 225-234
|
artikel
|
| 8 |
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer
|
Blok, Erik J.
|
|
2018
|
171 |
1 |
p. 65-74
|
artikel
|
| 9 |
Gene expression in triple-negative breast cancer in relation to survival
|
Wang, Shuyang
|
|
2018
|
171 |
1 |
p. 199-207
|
artikel
|
| 10 |
Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants
|
Fraile-Bethencourt, Eugenia
|
|
2018
|
171 |
1 |
p. 53-63
|
artikel
|
| 11 |
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
|
Telli, M. L.
|
|
2018
|
171 |
1 |
p. 21-31
|
artikel
|
| 12 |
Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
|
Lu, Christine Y.
|
|
2018
|
171 |
1 |
p. 235-242
|
artikel
|
| 13 |
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database
|
Choi, Jung Yoon
|
|
2018
|
171 |
1 |
p. 181-188
|
artikel
|
| 14 |
Incorporation of the technologist’s opinion for arbitration of discrepant assessments among radiologists at screening mammography
|
Coolen, Angela M. P.
|
|
2018
|
171 |
1 |
p. 143-149
|
artikel
|
| 15 |
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
|
Daniels, Benjamin
|
|
2018
|
171 |
1 |
p. 151-159
|
artikel
|
| 16 |
Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)
|
Williamson, Timothy J.
|
|
2018
|
171 |
1 |
p. 75-84
|
artikel
|
| 17 |
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
|
Hoste, G.
|
|
2018
|
171 |
1 |
p. 131-141
|
artikel
|
| 18 |
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
|
Bardia, Aditya
|
|
2018
|
171 |
1 |
p. 111-120
|
artikel
|
| 19 |
Predictors of surveillance mammography outcomes in women with a personal history of breast cancer
|
Lowry, Kathryn P.
|
|
2018
|
171 |
1 |
p. 209-215
|
artikel
|
| 20 |
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
|
O’Loughlin, Mark
|
|
2018
|
171 |
1 |
p. 1-9
|
artikel
|
| 21 |
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ
|
Wadsten, C.
|
|
2018
|
171 |
1 |
p. 95-101
|
artikel
|
| 22 |
SNP rs2071095 in LincRNA H19 is associated with breast cancer risk
|
Cui, Ping
|
|
2018
|
171 |
1 |
p. 161-171
|
artikel
|
| 23 |
Tamoxifen-induced fatty liver disease in a Caucasian patient
|
Eechoute, Karel
|
|
2018
|
171 |
1 |
p. 243-244
|
artikel
|
| 24 |
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway
|
Ono, Hisako
|
|
2018
|
171 |
1 |
p. 43-52
|
artikel
|
| 25 |
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy
|
Poggio, Francesca
|
|
2018
|
171 |
1 |
p. 245-246
|
artikel
|
| 26 |
Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists
|
Murciano-Goroff, Yonina R.
|
|
2018
|
171 |
1 |
p. 173-180
|
artikel
|
| 27 |
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
|
Abraham, Jame
|
|
2018
|
171 |
1 |
p. 11-20
|
artikel
|
Tijdschrift beschrijving